Qian yuhao is a high-tech enterprise in Beijing, and has been awarded a number of national and provincial science and technology awards and has strong scientific research and development strength. Along with the national policy guidance and technical prog
Under the background of the company's product leadership strategy, QYH has continuously cooperated with domestic and foreign research institutes to create a unified research and development platform to realize technology and resource sharing. Through the established unified research and development platform, it increases the research and development of its own intellectual property products. Focus on the development, introduction, absorption, digestion and redevelopment of new products and technologies, and on the establishment of diagnostic and pathogen isolation and identification platforms, genetic engineering technology construction platforms, large-scale animal cell culture platforms, new adjuvant research and application platforms, and new vaccine development platforms, to enhance the company's research and development capabilities, and provide a strong guarantee for the long-term development of the company.
In product technology, it focuses on the development of new technologies such as suspension culture and new adjuvants (immunopotentiators); promotes the improvement of production processes; continuously optimizes the process of vaccine concentration and purification; sub-cultures cell production processes; and focuses on creating high-quality products and high-end products. Based on high-end, it carries out research on new vaccines and has outstanding research achievements in subunit vaccines, genetic engineering vaccines, nucleic acid vaccines and new vaccines.